Exclusive video interview: Human Longevity Inc.’s Chairman

After $0.5bn cumulative investment, Human Longevity Inc. pivots into high-end medical services to seek scale and ROI.

For a few years we tracked Human Longevity Inc.’s press statements and found it hard to put the pieces together to establish if progress was being made. Then in November 2019 boom: $30m investment, on top of the previous $220m Series B, led by Emerging Technology Partners.

Longevity.Technology: We expected that our interview with Human Longevity Inc.’s Chairman, Dr Wei-Wu He, would be guarded and ambiguous: not a bit of it.

Dr He was effusive and very forthcoming with details on the company’s growth plans, changing structures, science and how they plan to be at the forefront of preventative medicine – not just helping the rich live longer and healthier, but looking for scale and wide scale adoption.

The company’s beachhead is its ‘Health Nucleus’ clinic in San Diego and Human Longevity Inc. is committed to build its next clinic in the Bay Area, near San Francisco airport, followed by more clinics in major cities around the world, including London.

Here’s a link to the video on LongevityTV. Enjoy.

Phil Newman
Editor-in-Chief Phil has over 25 years of C-level management, marketing and business development expertise in Europe and North America. His creative background has helped him shape unconventional strategies for commercial growth - garnering both awards and investor ROI.

Phil has wide experience of technology transfer and the commercialisation of innovations from both private and institutional sources and this led to his interest in Longevity and the founding of Longevity.Technology.

Latest articles

Fountain’s ‘hypothesis-free’ approach to Longevity AI

We reached out to Fountain’s CEO John Dimos to see what more we can learn about the mysterious San Francisco start-up. When it comes to...

G3 and Juvenescence partner on deep learning venture

G3 Therapeutics and Juvenescence announce the formation of Juvenomics to apply deep molecular profiling and deep learning to tackle aging. Juvenomics, a joint venture between...

Building an artificial immune system

DoD-funded ThirdLaw Technologies to harness the power of ‘spiroligomers’ to rapidly build new small molecules for Longevity therapies. Far from the world of stock market...

Neurotech is the new blue ocean

Alon Braun, Co-Founder, Neurotech Analytics.